- Home
- RMMZ vs ANEB Comparison
RMMZ vs ANEB Comparison
Compare RMMZ & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMMZ
- ANEB
- Stock Information
- Founded
- RMMZ 2022
- ANEB 2020
- Country
- RMMZ United States
- ANEB United States
- Employees
- RMMZ N/A
- ANEB N/A
- Industry
- RMMZ Investment Managers
- ANEB Biotechnology: Pharmaceutical Preparations
- Sector
- RMMZ Finance
- ANEB Health Care
- Exchange
- RMMZ Nasdaq
- ANEB Nasdaq
- Market Cap
- RMMZ 126.0M
- ANEB 111.8M
- IPO Year
- RMMZ N/A
- ANEB 2021
- Fundamental
- Price
- RMMZ $15.11
- ANEB $2.64
- Analyst Decision
- RMMZ
- ANEB Buy
- Analyst Count
- RMMZ 0
- ANEB 2
- Target Price
- RMMZ N/A
- ANEB $8.00
- AVG Volume (30 Days)
- RMMZ 25.6K
- ANEB 20.2K
- Earning Date
- RMMZ 01-01-0001
- ANEB 11-14-2025
- Dividend Yield
- RMMZ 7.33%
- ANEB N/A
- EPS Growth
- RMMZ N/A
- ANEB N/A
- EPS
- RMMZ 0.82
- ANEB N/A
- Revenue
- RMMZ N/A
- ANEB N/A
- Revenue This Year
- RMMZ N/A
- ANEB N/A
- Revenue Next Year
- RMMZ N/A
- ANEB N/A
- P/E Ratio
- RMMZ $19.41
- ANEB N/A
- Revenue Growth
- RMMZ N/A
- ANEB N/A
- 52 Week Low
- RMMZ $12.92
- ANEB $0.80
- 52 Week High
- RMMZ $16.99
- ANEB $3.42
- Technical
- Relative Strength Index (RSI)
- RMMZ 57.30
- ANEB 55.13
- Support Level
- RMMZ $14.94
- ANEB $2.50
- Resistance Level
- RMMZ $15.15
- ANEB $2.76
- Average True Range (ATR)
- RMMZ 0.19
- ANEB 0.13
- MACD
- RMMZ 0.01
- ANEB 0.00
- Stochastic Oscillator
- RMMZ 90.24
- ANEB 61.82
About RMMZ RiverNorth Managed Duration Municipal Income Fund II Inc.
RiverNorth Managed Duration Municipal Income Fund II Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.